Filing Flows › Ensysce Biosciences (ENSC) › Q1 2026
Ensysce Biosciences (ENSC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Ensysce Biosciences (ENSC) reported revenue of $961K for the first quarter 2026 (Q1 2026), -27% from a year earlier and -49% from the quarter before. Operating margin was -370.7%, net loss $3.6M (370.1% of revenue).
Ensysce Biosciences, Q1 2026: revenue $961K (-27% year over year), operating margin -370.7%, net loss $3.6M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $961K | -49% | -27% |
| Operating profit | −$3.6M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$3.5M | — | — |
What changed
Revenue was $1.0M in Q1 2026, down 27% year over year and down 49% from the previous quarter.
Operating costs exceeded revenue by $3.6M, an operating margin of -370.7%. Total costs grew 38% against a revenue fall of 27%. The fastest-growing cost line was Research & development (+78%). The quarter ended with a net loss of $3.6M, wider than the previous quarter's $2.8M loss.
Operating cash flow was −$3.5M. Non-cash charges added back $7K of depreciation and $9K of share-based compensation.
Questions
What was Ensysce Biosciences' revenue in the first quarter 2026?
Ensysce Biosciences (ENSC) reported revenue of $961K for the first quarter 2026 (Q1 2026), -27% from a year earlier and -49% from the quarter before.
Was Ensysce Biosciences profitable in the first quarter 2026?
Operating loss was $3.6M (-370.7% of revenue) and net loss $3.6M.